Multiple Sclerosis Therapeutics Book

	Contributors
	Preface to First edition
	Preface to second edition
	Acknowledgements
I	Introduction
1	Aspects of multiple sclerosis that relate to clinical trial design and treatment	3
II	Clinical trial methodology
2	Measures of neurologic impairment and disability in multiple sclerosis	23
3	Assessment of neuropsychological function in multiple sclerosis	37
4	Health-related quality of life assessment in multiple sclerosis	61
5	Magnetic resonance imaging in multiple sclerosis: an overview	81
6	Measures of gadolinium enhancement in multiple sclerosis	97
7	Measures of magnetization transfer in multiple sclerosis	125
8	Measures of T1 and T2 relaxation in multiple sclerosis	155
9	Measurement of central nervous system atrophy in multiple sclerosis	173
10	Measures to quantify axonal damage in vivo based on magnetic resonance spectroscopy in multiple sclerosis	193
11	Functional imaging in multiple sclerosis	207
12	Use of cost analyses to improve our understanding of the therapeutic trade-offs for multiple sclerosis	221
13	Ethical considerations in multiple sclerosis clinical trials	231
14	The process of drug development and approval in the USA, the European Union and Canada	241
15	Sponsors, monitoring committees and investigators: the investigator's perspective	257
16	Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials	261
17	The failed clinical trial in multiple sclerosis	267
18	The challenge of long-term studies in multiple sclerosis: use of pooled data, historical controls, and observational studies to determine efficacy	277
19	Emerging concepts of pathogenesis: relationship to MS therapies	289
III	Clinical trials of disease-modifying therapy
20	Interferons in relapsing-remitting multiple sclerosis	325
21	Interferons in secondary progressive multiple sclerosis	347
22	Biological responses to type I interferons: relationship to therapeutic effects in multiple sclerosis	363
23	Glatiramer acetate as therapy for multiple sclerosis	379
24	Use of mitoxantrone to treat multiple sclerosis	403
25	Intravenous immunoglobulin to treat multiple sclerosis	427
26	Therapeutic plasma exchange for multiple sclerosis	445
27	Treatment of multiple sclerosis with methylprednisolone	461
28	Cyclophosphamide treatment of multiple sclerosis	483
29	Treatment of multiple sclerosis by hematopoietic stem cell transplantation	501
30	Emerging disease-modifying therapies for multiple sclerosis	515
31	Combination therapies in multiple sclerosis	523
32	Sex hormones and other pregnancy-related factors with therapeutic potential in multiple sclerosis	535
33	Complementary and alternative treatments in multiple sclerosis	551
IV	Disease-modifying drug therapy in clinical practice
34	Disease-modifying drug therapy for multiple sclerosis in clinical practice	567
35	Treatment for patients with primary progressive multiple sclerosis	589
36	Fatigue in multiple sclerosis	599
37	Management of spasticity in multiple sclerosis	609
38	Management of bladder and sexual dysfunction in multiple sclerosis	621
39	Treatment of disorders of mood and affect in multiple sclerosis	651
40	Treatment of pain, paresthesias, and paroxysmal disorders in multiple sclerosis	689
41	Treatment of tremor caused by multiple sclerosis	705
42	Management of cognitive impairment in multiple sclerosis	715
43	Rehabilitation in multiple sclerosis patients	729